A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial

Trial Profile

A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Temsirolimus (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STORM
  • Most Recent Events

    • 06 Dec 2016 Results (n=46) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Dec 2015 Results of part 1 of this study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top